Opinion

Published within

« | ... | 1565 | 1566 | 1567 | 1568 | 1569 | 1570 | 1571 | 1572 | 1573 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Biosante: testosterone gel to combat FSD

Published By Datamonitor
18 May 2001
CommentWire
CommentWire

Biopure: sterile oxygen therapeutic set for success

Published By Datamonitor
17 Apr 2001
Expert View
Expert View

Bioprospecting the natural choice for drug discovery

Published By Datamonitor
23 Mar 2001
Expert View
Expert View

Bionym brings biometric authentication to wearables

Bionym's multi-bank trial of Nymi Band will see the start-up capitalize on the rising ownership of contactless payment cards in Canada, tapping into the growing use of biometrics as a payment authentication tool.

Published By Datamonitor
17 Nov 2014
CommentWire
CommentWire

Bionx Implants: new Meniscus Arrow should maintain share

The Contour Mensiscus Arrow is an updated version of Bionx's popular Meniscus Arrow. The new product is likely to rejuvenate Bionx' declining share of the meniscal repair market. Indeed, it should enable the company to take an even greater share of this market, which Datamonitor expects to be worth $42.8 million by 2005 in the US alone.

Published By Datamonitor
19 Nov 2001
Expert View
Expert View

BiondVax: new Phase II data heat up the race for the first universal influenza vaccine

New data presented at the World Vaccines Congress demonstrate that BiondVax's developmental influenza vaccine can also act as a booster to existing seasonal influenza vaccines in elderly patients. A vaccine with increased efficacy in the elderly is one of the largest unmet needs in influenza prevention, although the need for patients to take multiple vaccinations may hinder its success.

Published By Datamonitor
13 Apr 2012
CommentWire
CommentWire

BioMS Medical: potential to broaden MS treatment options

BioMS has initiated an open-label extension of its MAESTRO-01 pivotal phase II/III trial of MBP-8298 in patients with secondary progressive multiple sclerosis. MBP-8298 has the potential to broaden the currently narrow treatment options for this form of MS as well as offering an improved dosing regimen.

Published By Datamonitor
02 Mar 2007
CommentWire
CommentWire

Biomira/Merck KGaA: positive data for cancer vaccine

A phase IIb trial has shown a clinically significant improvement to median survival when the L-BLP25 vaccine is used as second-line treatment of advanced non-small cell lung cancer (NSCLC). However, further randomized clinical trials are required before the vaccine can achieve significant uptake.

Published By Datamonitor
06 Apr 2004
CommentWire
CommentWire

Biometric banking technology: the future is now

In an attempt to offer increased convenience and protection to customers, the Japanese Bankers Association has announced plans to establish a standardized biometric customer identification system. If the technology proves successful, other banks may follow suit, although numerous concerns need to be overcome before this can become a reality.

Published By Datamonitor
14 Jul 2005
CommentWire
CommentWire

BioMarin: Phenoptin to achieve rapid uptake

Phenoptin, BioMarin's late-stage product candidate, is likely to become the first approved treatment for phenylketonuria, a rare genetic metabolic disorder that affects approximately one in 12,000 births in the US. Given this unmet need, Datamonitor expects Phenoptin to gain US approval in late 2007 with sales forecast to reach $161 million in 2008, almost double that of Wall Street consensus.

Published By Datamonitor
12 Oct 2006

« | ... | 1565 | 1566 | 1567 | 1568 | 1569 | 1570 | 1571 | 1572 | 1573 | ... | » »|

No help is available.